UB567
TargetsCEA/CDH17
IndicationsGastrointestinal cancer
ClinicalCN - Pre-PCC
TherapeuticsOncology
ModalitiesADC
Exclusive Summary
- • Dual-target synergy to overcome tumor heterogeneity.
- • Significantly superior to other single-target ADCs.
- • Innovatively designed, stable, hydrophilic and cleavable Exatecan-based linker-payload.
Asset Materials
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →